Core Insights - The health care sector has several oversold stocks that present buying opportunities for undervalued companies [1] Group 1: Oversold Stocks - Travere Therapeutics Inc (NASDAQ:TVTX) has an RSI of 29.7, with a stock price decline of approximately 23% over the past month and a 52-week low of $12.91 [6] - Hims & Hers Health Inc (NYSE:HIMS) has an RSI of 29.7, with a stock price decline of around 13% over the past month and a 52-week low of $23.97 [6] - Enovis Corp (NYSE:ENOV) has an RSI of 29.6, with a stock price decline of about 14% over the past five days and a 52-week low of $22.98 [6] Group 2: Analyst Ratings and Price Targets - Evercore ISI Group initiated coverage on Hims & Hers Health with an In-Line rating and a price target of $33 [6] - BTIG analyst initiated coverage on Enovis with a Buy rating and a price target of $41 [6] - Travere Therapeutics' new PDUFA target action date for Filspari is set for April 13 [6]

Core Insights - The health care sector shows potential investment opportunities as several stocks are identified as oversold, with Relative Strength Index (RSI) values near or below 30, indicating they may be undervalued [1][2] Company Summaries - **Travere Therapeutics Inc (NASDAQ:TVTX)**: The company’s stock has fallen approximately 23% over the past month, reaching a 52-week low of $12.91. The RSI value is 29.7, and the stock closed at $27.94, with a momentum score of 91.85 [3][6] - **Hims & Hers Health Inc (NYSE:HIMS)**: The stock has decreased around 13% in the last month, with a 52-week low of $23.97. The RSI value is 29.7, and shares closed at $30.47 after a 2.9% drop [4][6] - **Enovis Corp (NYSE:ENOV)**: The stock has seen a decline of about 14% over the past five days, with a 52-week low of $22.98. The RSI value is 29.6, and shares closed at $23.09, down 3.7% [5][6]

Core Viewpoint - Shares of Travere Therapeutics (TVTX) declined by 14.6% following the FDA's announcement to extend the review timeline for the supplemental new drug application (sNDA) for Filspari in the FSGS indication by three months, with a new decision date set for April 13, 2026 [1][7]. FDA Review Extension - The FDA extended the review timeline after Travere submitted additional information to better define the clinical benefit of Filspari, classifying these submissions as a major amendment to the sNDA [2]. - No new safety or manufacturing data was requested by the FDA for Filspari [2]. Product Information - Filspari is currently approved to slow kidney function decline in adults with primary IgA nephropathy at risk of disease progression [3]. - FSGS is a rare kidney disorder affecting over 40,000 patients in the U.S. and a similar number in the EU, characterized by progressive kidney scarring and proteinuria [5][8]. - If approved for FSGS, Filspari would be the first FDA-approved therapy for this condition, addressing podocyte injury, a critical factor in FSGS progression [8]. Market Performance - Over the past six months, Travere Therapeutics' shares have increased by 72.1%, outperforming the industry average increase of 20.4% [4]. Financial Projections - Preliminary sales for Q4 2025 are expected to be around $127 million, with full-year 2025 net product sales projected at approximately $410 million in the U.S. [10]. - Preliminary U.S. net product sales of Filspari for Q4 2025 are estimated at $103 million, reflecting a 108% year-over-year increase, with full-year sales around $322 million [11]. Partnerships and Future Plans - In October 2025, Travere received a $40 million milestone payment from CSL Vifor after achieving market access milestones, with further payments expected tied to additional market access and sales [12]. - The company plans to continue building clinical evidence to support Filspari as a foundational treatment for IgAN through ongoing clinical studies, with the potential label expansion for FSGS likely to boost sales in 2026 [13].

Core Insights - Novartis announced positive final results from the late-stage APPLAUSE-IgAN study on Fabhalta (iptacopan) for adults with IgA nephropathy (IgAN), showing significant efficacy in slowing disease progression [1][2][8] - Fabhalta received accelerated approval in the U.S. in August 2024 for reducing proteinuria in adults with IgAN at risk of rapid disease progression [1] - The positive study results will support Novartis' regulatory submission for traditional FDA approval in 2026 [3][8] Drug Approvals and Pipeline - Fabhalta has received FDA and European Commission approval for treating adults with paroxysmal nocturnal hemoglobinuria (PNH) and is also approved in China for IgAN [4] - The drug is being evaluated for various rare kidney diseases, including atypical hemolytic uremic syndrome and lupus nephritis [5] - Novartis' portfolio includes other candidates like Vanrafia (atrasentan) and zigakibart for IgAN [5] Competitive Landscape - Travere Therapeutics' Filspari (sparsentan) is also approved for slowing kidney function decline in adults with primary IgAN [5][6] - Filspari received full approval in September 2024 based on long-term results from the PROTECT study [6] Financial Performance and Strategic Moves - Novartis has shown strong performance, with shares gaining 36.7% year-to-date compared to the industry's 7.5% growth [9] - The company is focused on strategic acquisitions, including the planned acquisition of Tourmaline Bio, Inc. for $1.4 billion, which will enhance its cardiovascular pipeline [11][12] - Novartis aims to strengthen its pipeline through both organic growth and acquisitions [11]

Group 1 - The article discusses the performance and outlook of Travere Therapeutics, Inc. (NASDAQ: TVTX), highlighting its recent approval for the therapy Filspari (sparsentan) [1] - The author provides insights into the biotech, pharma, and healthcare industries, emphasizing the importance of understanding key trends and catalysts that drive valuations [1] - The investing group Haggerston BioHealth offers resources for both novice and experienced biotech investors, including product sales forecasts and market analysis [1] Group 2 - The article is authored by a biotech consultant with over five years of experience in the industry, who has prepared detailed reports on more than 1,000 companies [1] - The focus is on providing buy and sell ratings, as well as financial analyses such as discounted cash flow analysis [1]